NOVAST Laboratories, Limited (SZSE: 301569)
Health Care · Pharmaceuticals · CN
CN¥16.73
-2.96% today · -52.4% 1Y
NOVAST Laboratories, Limited (SZSE: 301569) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.24B and employs 697 people.
Over the last twelve months the share price has lost 52.4%, trading between 16.73 and 42.15.
Tweenvest scores NOVAST Laboratories, Limited across four factors: quality 83/100, value 4/100, growth 52/100. Its strongest factor is quality.
301569 price history
Key figures
- Market cap
- $2.24B
- Revenue (TTM)
- $150.54M
- P/E
- 40.88
- EPS
- 0.27
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- CN¥42.15
- 52-week low
- CN¥16.73
- Avg volume (3M)
- —
- Shares outstanding
- 891.60M
- Employees
- 697
- Next earnings
- —
About NOVAST Laboratories, Limited
NOVAST Laboratories, Limited develops, manufactures, and sells prescription drug formulations. The company produces controlled-release formulations, including extended-release and sustained-release tablets and capsules, as well as low-dose drug formulations. Its products include Metoprolol Succinate Extended-Release Tablets, Nifedipine Extended-Release Tablets, Diltiazem Hydrochloride Extended-Release Capsules, Metformin Hydrochloride Sustained-Release Tablets, Levonorgestrel Tablets, Memantine Hydrochloride Extended-Release Capsules, Quetiapine Fumarate Sustained-Release Tablets, and Tolterodine tablets for urinary frequency and urgency. The company also develops a digestive-system extended-release tablet designated DG-062. Additionally, the company provides formulation contract research organization (CRO) services, including prescription process development and regulatory filing and clinical support services for pharmaceutical companies and research institutions, as well as outsourced CRO and contract manufacturing organization (CMO) services for innovative drugs. NOVAST Laboratories, Limited was incorporated in 2005 and is based in Nantong, China.
- ISIN
- CNE1000080W6
- Founded
- 2005
- Listed since
- Oct 15, 2026
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Aether Industries LimitedNSEI: AETHER | $2.36B | Rs1,677.20 | -0.72% |
| China Resources Jiangzhong Pharmaceutical Co.,LtdSHSE: 600750 | $2.30B | CN¥24.40 | +2.18% |
| Shandong Buchang Pharmaceuticals Co., Ltd.SHSE: 603858 | $2.28B | CN¥14.65 | -1.61% |
| Pharvaris N.V.NasdaqGS: PHVS | $2.28B | $32.44 | -2.76% |
| Zhejiang Hisun Pharmaceutical Co., Ltd.SHSE: 600267 | $2.23B | CN¥12.87 | -3.52% |
| Tonghua Dongbao Pharmaceutical Co., Ltd.SHSE: 600867 | $2.23B | CN¥7.60 | -0.65% |
| Perrigo Company plcNYSE: PRGO | $2.23B | $16.04 | -5.31% |
| Jamjoom Pharmaceuticals Factory CompanySASE: 4015 | $2.22B | SR119.20 | +1.79% |